The US Patent and Trademark Office (USPTO) has granted a patent to specialty pharma company AMAG Pharmaceuticals, for its ferumoxytol drug, which is used to heal anemia caused by iron deficiency.
The company has been given US Patent No. 8,501,158, Polyol and Polyether Iron Oxide Complexes as pharmacological and/or MRI contrast agents, for the use of 500mg -600mg of ferumoxytol, which will expire in 2020.
AMAG chief operating officer Frank Thomas said, "We believe that this issued patent complements and expands our intellectual property protection for ferumoxytol, providing further specific claims related to approved dosing and formulation."
Currently, the pharma company has four Orange Book listed patents for ferumoxytol, with patent protection through 2020, without patent term extension.
A patent term extension application has been submitted for an Orange Book listed ferumoxytol patent to extend up to June 2023.
